BACKGROUND: The clinical significance of slow recovery of graft function (SGF) in living donor kidney transplantation is unclear. We evaluated the incidence, risk factors, and clinical outcome of SGF in living donor transplantation. METHODS: Three hundred ten living donor kidney recipients were included and categorized into immediate recovery of graft function (IGF; n=239) and SGF (n=71), according to estimated glomerular filtration rate (60 mL/min/1.73 m) at posttransplant day 14. We compared the clinical parameters, protocol biopsy findings, acute rejection (AR), and 10-year graft survival between the two groups. RESULTS: The SGF group had an older recipient age, lower ratio of donor to recipient body mass index, and higher incidence of AR than IGF group, as shown by protocol biopsies. The SGF group had significantly more AR episodes than IGF group within 12 months (21.1% vs. 13.4%, P<0.05) and during follow-up period (32.4% vs. 20.1%, P<0.05). The 10-year graft survival rate did not differ between groups, but AR presence was significantly associated with a lower graft survival in the SGF group than the IGF group (64.9% vs. 78.9%, P<0.05). CONCLUSIONS: SGF in the early posttransplant period is immunologically active and should be considered as one of the risk factors for determining long-term graft survival in living donor kidney transplantation.
BACKGROUND: The clinical significance of slow recovery of graft function (SGF) in living donor kidney transplantation is unclear. We evaluated the incidence, risk factors, and clinical outcome of SGF in living donor transplantation. METHODS: Three hundred ten living donor kidney recipients were included and categorized into immediate recovery of graft function (IGF; n=239) and SGF (n=71), according to estimated glomerular filtration rate (60 mL/min/1.73 m) at posttransplant day 14. We compared the clinical parameters, protocol biopsy findings, acute rejection (AR), and 10-year graft survival between the two groups. RESULTS: The SGF group had an older recipient age, lower ratio of donor to recipient body mass index, and higher incidence of AR than IGF group, as shown by protocol biopsies. The SGF group had significantly more AR episodes than IGF group within 12 months (21.1% vs. 13.4%, P<0.05) and during follow-up period (32.4% vs. 20.1%, P<0.05). The 10-year graft survival rate did not differ between groups, but AR presence was significantly associated with a lower graft survival in the SGF group than the IGF group (64.9% vs. 78.9%, P<0.05). CONCLUSIONS: SGF in the early posttransplant period is immunologically active and should be considered as one of the risk factors for determining long-term graft survival in living donor kidney transplantation.
Authors: Byung H Chung; Hye J Oh; Shang G Piao; Hyeon S Hwang; In O Sun; Sun R Choi; Hoon S Park; Bum S Choi; Yeong J Choi; Cheol W Park; Yong-Soo Kim; Mi-La Cho; Chul W Yang Journal: Immunology Date: 2012-07 Impact factor: 7.397
Authors: Hari V Kalluri; Puneet Sood; Wenchen Zhao; Parmjeet S Randhawa; Amit D Tevar; Sundaram Hariharan; Abhinav Humar; Raman Venkataramanan Journal: Transplant Direct Date: 2020-05-28
Authors: J Hellegering; J Visser; H J Kloke; F C H D'Ancona; A J Hoitsma; J A van der Vliet; M C Warlé Journal: World J Urol Date: 2012-02-14 Impact factor: 4.226